Stock GLS GLENMARK LIFE SCIENCES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Glenmark Life Sciences Limited Bombay S.E.

Equities

GLS

INE03Q201024

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 03:30:47 10/05/2024 pm IST 		5-day change 1st Jan Change
826.4 INR -1.01% Intraday chart for Glenmark Life Sciences Limited -0.37% +25.76%
25/04 Transcript : Glenmark Life Sciences Limited, Q4 2024 Earnings Call, Apr 25, 2024
25/04 Glenmark Life Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: März 2022 2023 2024 2025 2026
Capitalization 1 56,215 48,141 1,01,422 - -
Enterprise Value (EV) 1 51,123 45,047 95,161 1,01,422 1,01,422
P/E ratio 12.9 x 10.3 x 20.2 x 18.4 x 16.1 x
Yield 2.29% 5.34% 2.55% 2.91% 3.03%
Capitalization / Revenue 2.63 x 2.23 x 4.17 x 3.93 x 3.43 x
EV / Revenue 2.39 x 2.08 x 4.17 x 3.93 x 3.43 x
EV / EBITDA 8.1 x 7.01 x 14.1 x 12.9 x 11.1 x
EV / FCF 11.3 x 31.5 x 32 x 47.7 x 40.2 x
FCF Yield 8.85% 3.18% 3.12% 2.1% 2.49%
Price to Book - 2.25 x 4.09 x 3.6 x 3.08 x
Nbr of stocks (in thousands) 1,22,527 1,22,527 1,22,527 - -
Reference price 2 458.8 392.9 827.8 827.8 827.8
Announcement Date 20/04/22 27/04/23 25/04/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: März 2021 2022 2023 2024 2025 2026
Net sales 1 18,852 21,379 21,612 22,832 25,787 29,542
EBITDA 1 - 6,308 6,423 6,742 7,887 9,120
EBIT 1 - 5,929 6,002 6,208 7,339 8,414
Operating Margin - 27.73% 27.77% 27.19% 28.46% 28.48%
Earnings before Tax (EBT) 1 - 5,649 6,286 6,313 7,517 8,489
Net income 1 - 4,187 4,670 4,709 5,504 6,307
Net margin - 19.59% 21.61% 20.62% 21.35% 21.35%
EPS 2 - 35.63 38.11 38.38 44.87 51.41
Free Cash Flow 1 - 4,524 1,432 3,056 2,127 2,525
FCF margin - 21.16% 6.63% 12.78% 8.25% 8.55%
FCF Conversion (EBITDA) - 71.73% 22.3% 41.56% 26.97% 27.69%
FCF Conversion (Net income) - 108.05% 30.67% 58.63% 38.64% 40.04%
Dividend per Share 2 - 10.50 21.00 21.10 24.07 25.07
Announcement Date 20/07/21 20/04/22 27/04/23 25/04/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: März 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 5,638 5,260 5,192 4,994 5,093 5,407 6,213 5,784 5,980 6,025 6,070
EBITDA 1 - 1,496 - 1,468 1,436 1,455 2,064 1,932 2,012 1,693 1,702
EBIT 1 1,598 1,399 1,378 1,464 1,437 1,413 1,949 1,824 1,947 - 1,708
Operating Margin 28.33% 26.59% 26.53% 29.31% 28.22% 26.13% 31.37% 31.53% 32.56% - 28.14%
Earnings before Tax (EBT) 1 - - - - - - - 1,820 - - 1,729
Net income 1 - 1,037 - 1,087 1,069 1,050 1,464 1,354 1,419 1,182 1,176
Net margin - 19.72% - 21.77% 20.99% 19.42% 23.56% 23.42% 23.73% 19.62% 19.36%
EPS 2 - - - - - - - 11.05 - - 10.40
Dividend per Share - - - - - - - - - - -
Announcement Date 10/11/21 08/02/22 20/04/22 04/08/22 21/10/22 27/01/23 27/04/23 21/07/23 - - -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: März 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - -
Net Cash position 1 - 5,093 3,094 3,498 - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 - 4,524 1,432 3,056 2,127 2,525
ROE (net income / shareholders' equity) - 29.8% 22.3% 22.7% 21.9% 21.9%
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share 2 - - 175.0 202.0 230.0 269.0
Cash Flow per Share - - - - - -
Capex 1 - 1,452 1,702 1,606 3,333 2,833
Capex / Sales - 6.79% 7.87% 6.72% 12.93% 9.59%
Announcement Date 20/07/21 20/04/22 27/04/23 25/04/24 - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Glenmark Life Sciences Limited

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
827.8 INR
Average target price
905.8 INR
Spread / Average Target
+9.42%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+30.38% 684B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.36% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.30% 329B
ABBVIE INC. Stock AbbVie Inc.
+3.73% 284B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.70% 240B
NOVARTIS AG Stock Novartis AG
+8.78% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-7.93% 200B
AMGEN INC. Stock Amgen Inc.
+7.68% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GLS Stock
  4. GLS Stock
  5. Financials Glenmark Life Sciences Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW